A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome)

Espinoza, Jimmy; Romero, Roberto; Nien, Jyh Kae; Kusanovic, Juan Pedro; Richani, Karina; Gomez, Ricardo; Kim, Chong Jai; Mittal, Pooja; Gotsh, Francesca; Erez, Offer; Chaiworapongsa, Tinnakorn; Hassan, Sonia S.

doi:10.1080/14767050600922677

Cited by 97 publications

(104 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recent evidence suggests that it may be a mechanism of disease in other obstetrical syndromes as well, such as fetal death [79], mirror syndrome [80], and SGA [20]. Indeed, Levine et al [27] reported that normotensive patients who delivered an SGA neonate have a higher maternal serum concentration of sEng compared to controls beginning at 17 to 20 weeks of gestation, and that that difference was higher at 37 to 42 weeks.…”

Section: Endoglin and S-engmentioning

confidence: 99%

See 1 more Smart Citation

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Romero

Nien²,

Espinoza

et al. 2008

The Journal of Maternal-Fetal & Neonatal Medicine

Self Cite

622

502

View full text Add to dashboard Cite

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate, The Journal of Maternal-Fetal & Neonatal Medicine, 21:1, 9-23, DOI: 10.1080/14767050701830480 To link to this article: https://doi.org/10.1080/14767050701830480 Abstract Introduction. Accumulating evidence suggests that an imbalance between pro-angiogenic (i.e., vascular endothelial growth factor (VEGF) and placental growth factor (PlGF)) and anti-angiogenic factors (i.e., soluble VEGF receptor-1 (sVEGFR-1, also referred to as sFlt1)) is involved in the pathophysiology of preeclampsia (PE). Endoglin is a protein that regulates the pro-angiogenic effects of transforming growth factor b, and its soluble form has recently been implicated in the pathophysiology of PE. The objective of this study was to determine if changes in maternal plasma concentration of these angiogenic and anti-angiogenic factors differ prior to development of disease among patients with normal pregnancies and those destined to develop PE (preterm and term) or to deliver a small for gestational age (SGA) neonate. Methods. This longitudinal nested case-control study included 144 singleton pregnancies in the following groups: (1) patients with uncomplicated pregnancies who delivered appropriate for gestational age (AGA) neonates (n ¼ 46); (2) patients who delivered an SGA neonate but did not develop PE (n ¼ 56); and (3) patients who developed PE (n ¼ 42). Longitudinal samples were collected at each prenatal visit, scheduled at 4-week intervals from the first or early second trimester until delivery. Plasma concentrations of soluble endoglin (s-Eng), sVEGFR-1, and PlGF were determined by specific and sensitive ELISA. Results. (1) Patients destined to deliver an SGA neonate had higher plasma concentrations of s-Eng throughout gestation than those with normal pregnancies; (2) patients destined to develop preterm PE and term PE had significantly higher concentrations of s-Eng than those with normal pregnancies at 23 and 30 weeks, respectively (for preterm PE: p 5 0.036 and for term PE: p ¼ 0.002); (3) patients destined to develop PE (term or preterm) and those who delivered an SGA neonate had lower plasma concentrations of PlGF than those with a normal pregnancy throughout gestation, and the maternal plasma concentration of this analyte became detectable later among patients with pregnancy complications, compared to normal pregnant women; (4) there were no significant differences in the plasma concentrations of sVEGFR-1 between patients destined to deliver an SGA neonate and those with normal pregnancies; (5) patients destined to develop preterm and term PE had a significantly higher plasma concentration of sVEGFR-1 at 26 and 29 weeks of gestation than controls (p ¼ 0.009 and p ¼ 0.0199, respectively); and (6) there was no significant difference in the increment of sVEGF...

show abstract

Section: Endoglin and S-engmentioning

confidence: 99%

“…However, other pregnancy complications are also characterized by an antiangiogenic state such as placental abruption [83], 'mirror syndrome' [80,84,85], PE with parvovirusinduced hydrops [86], and unexplained fetal death [79].…”

Section: Maternal Plasma Plgf/s-eng Ratio In Pe and Sgamentioning

confidence: 99%

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Romero

Nien²,

Espinoza

et al. 2008

The Journal of Maternal-Fetal & Neonatal Medicine

Self Cite

622

502

View full text Add to dashboard Cite

show abstract

“…Preeclampsia [63][64][65][66][67]69,70,72,[92][93][94][95][96][97][98][99][100][101][102][103], as well as other obstetrical syndromes [46,[104][105][106][107][108][109][110][111][112][113][114][115][116][117][118], is characterized by an anti-angiogenic state. Plasma concentrations of the angiogenic factor, placental growth factor (PlGF), are decreased [69,70,92,93,96,[100][101][102], and the anti-angiogenic factors (soluble vascular endothelial growth factor receptor-1 [sVEGFR-1] and soluble endoglin [sEng]) are elevated both prior to [67,72,[119]…”

Section: Introductionmentioning

confidence: 99%

Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia

Stampalija

Chaiworapongsa

Romero

et al. 2013

The Journal of Maternal-Fetal & Neonatal Medicine

Self Cite

View full text Add to dashboard Cite

Objectives: Angiogenic/anti-angiogenic factors have emerged as one of the promising biomarkers for the prediction of preeclampsia. Since not all patients with preeclampsia can be identified by these analytes, the search for additional biomarkers continues. The soluble form of ST2 (sST2), a protein capable of binding to interleukin (IL)-33 and thus contributing to a Th1-biased immune response, has been reported to be elevated in maternal plasma of women with preeclampsia. The aims of this study were to examine: (1) differences in maternal plasma concentrations of sST2 and IL-33 between women diagnosed with preeclampsia and those having uncomplicated pregnancies; (2) the relationship between sST2, umbilical and uterine artery Doppler velocimetry, and the severity of preeclampsia; and (3) the performance of sST2 and angiogenic/anti-angiogenic factors in identifying patients with preeclampsia at the time of diagnosis. Methods: This cross-sectional study included women with preeclampsia (n ¼ 106) and women with an uncomplicated pregnancy (n ¼ 131). Plasma concentrations of sST2, IL-33, soluble vascular endothelial growth factor receptor (sVEGFR)-1, soluble endoglin (sEng) and placental growth factor (PlGF) were determined by enzyme linked immune sorbent assay. Area under the receiver operating characteristic curve (AUC) for the identification of preeclampsia was examined for each analyte. Results: (1) Patients with preeclampsia had a higher mean plasma concentrations of sST2 than those with an uncomplicated pregnancy (p50.0001), while no significant difference in the mean plasma concentration of IL-33 between the two groups was observed; (2) the magnitude of this difference was greater in early-onset, compared to late-onset disease, and in severe compared to mild preeclampsia; (3) sST2 plasma concentrations did not correlate with the results of uterine or umbilical artery Doppler velocimetry (p ¼ 0.7 and p ¼ 1, respectively) among women with preeclampsia; (4) sST2 correlated positively with plasma concentrations of sVEGFR1-1 and sEng (Spearman's Rho ¼ 0.72 and 0.63; each p50.0001), and negatively with PlGF (Spearman's Rho ¼ À0.56, p50.0001); and (5) while the AUC achieved by sST2 and angiogenic/anti-angiogenic factors in identifying women with preeclampsia at the time of diagnosis were non-significantly different prior to term (537 weeks of gestation), thereafter the AUC achieved by sST2 was significantly less than that achieved by angiogenic/anti-angiogenic factors. Conclusions: Preeclampsia is associated with increased maternal plasma concentrations of sST2. The findings that sST2 concentrations do not correlate with uterine or umbilical artery Doppler velocimetry in women with preeclampsia suggest that elevated maternal plasma sST2 concentrations in preeclampsia are not related to the increased impedance to flow in the uteroplacental circulation. The performance of sST2 in identifying preeclampsia at the time of diagnosis prior to 37 weeks of gestation was comparable to that of angiogenic/anti-angiogenic f...

show abstract

“…Initial reports have focused largely on preeclampsia [21,26,27,31,41,44,46,47,[49][50][51][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76]; however, recent studies indicate that an anti-angiogenic state in humans (as determined by the relative concentrations of placental growth factor, soluble Flt-1, and endoglin) is also present in other conditions such as SGA neonates [44,74,[77][78][79][80][81], mirror syndrome [82][83][84], placental abruption [85], twin-to-twin transfusion syndrome [86], and fetal death [87]. Several of these observations have been published in the Journal of Maternal-Fetal & Neonatal Medicine and are available via open access.…”

Section: The Role Of Angiogenic and Anti-angiogenic Factorsmentioning

confidence: 99%

The role of an ‘anti-angiogenic state’ in complications of pregnancy

Renzo

2008

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome)

Cited by 97 publications

References 28 publications

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia

The role of an ‘anti-angiogenic state’ in complications of pregnancy

Contact Info

Product

Resources

About